Last updated on July 2018

Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Narcolepsy | Cataplexy | Excessive Daytime Sleepiness
  • Age: Between 16 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Male or female subjects 16 years of age or older
  2. Willing and able to give written informed consent for study participation. For young adults (16 and 17 years old) who have not reached the age of majority they must be capable of giving assent and consent from a legally authorized guardian must be obtained, as required by local laws and regulations
  3. Documented evidence of a diagnosis of NT1 or NT2 as, in part, determined by an overnight PSG and next-day MSLT with 2 or more SOREMPs with mean sleep latency in the pathological range i.e. < 8 minutes and meeting the NT1 and NT2 as defined by the International Classification of Sleep Disorders -3 criteria.
  4. Current continuing presence of EDS as defined by subject report for the last 3 months and an ESS > 10
  5. For NT1 only, current continuing presence of cataplexy as defined by subject report for the last 3 months
  6. Subjects may use concomitant stimulants, but must comply with the following:
  7. They must be on a stable dose of stimulants for at least 3 weeks prior to starting the screening process for this study; AND
  8. They must use the same stimulant regimen throughout the entire study period, including during screening and posttreatment periods
  9. They must discontinue all anti cataplexy drugs
  10. Addition inclusion criteria per protocol

Exclusion criteria

  1. Any prior use of sodium oxybate
  2. Current use of sodium valproate
  3. Any use of the following prohibited medications for the duration of the clinical study
  • Anticonvulsants
  • Clonidine
  • SSRIs and serotonin and norepinephrine re-uptake inhibitors (SNRIs)
  • MAOIs
  • TSAs
  • Hypnotics
  • Anxiolytics
  • Sedating antihistamines
  • Antipsychotics
  • Other experimental medications designed to treat narcolepsy, cataplexy or any other condition
  • Treatment with any investigational products within 3 months before study enrollment
  • Any drug known to affect sleep-wake function. Concomitant stimulant use is permitted.

4. Additional exclusion criteria per protocol

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.